Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sylvia Bort‐Martí"'
Autor:
Vicente Ruiz‐García, Eduardo López‐Briz, Rafael Carbonell‐Sanchis, Sylvia Bort‐Martí, José Luis Gonzálvez‐Perales
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 9, Iss 3, Pp 444-452 (2018)
Abstract In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases
Externí odkaz:
https://doaj.org/article/a09fc9a140c448f7ab75e039bc08375f
Autor:
Angeles R. Bort-Martí, Fiona J Rowe, Laura Ruiz Sifre, Sueko M Ng, Sylvia Bort-Martí, Vicente Ruiz Garcia
Publikováno v:
Cochrane Database of Systematic Reviews. 2023
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba2855b2c9b68c02e473ff02460dd311
https://doi.org/10.1002/14651858.cd006499.pub5
https://doi.org/10.1002/14651858.cd006499.pub5
Autor:
Vicente, Ruiz-García, Eduardo, López-Briz, Rafael, Carbonell-Sanchis, Sylvia, Bort-Martí, José Luis, Gonzálvez-Perales
Publikováno v:
Journal of cachexia, sarcopenia and muscle. 9(3)
In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases appetite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d69ba2585bce2e6a1462e6d326e32ec4
https://pubmed.ncbi.nlm.nih.gov/29542279
https://pubmed.ncbi.nlm.nih.gov/29542279
Publikováno v:
American Journal of Medical Genetics. 114:46-50
In the present study, we sought to identify genetic variation in the metabotropic glutamate receptor 3 (GRM3) gene, which has been mapped to chromosome 7q21.1-q21.2 [Scherer et al., 1996] and might contribute to genetic predisposition to schizophreni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62960a964566f34a688ea0fda6bba322
https://doi.org/10.1002/ajmg.1624
https://doi.org/10.1002/ajmg.1624
Publikováno v:
American Journal of Medical Genetics. 114:12-14
Imbalances in glutamatergic function have been implicated in the pathogenesis of neuropsychiatric disorders. Consequently, glutamate receptors genes are promising candidates in search of susceptibility genes for these disorders. In the present study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83f36bd498f2f5d925919073c82b0542
https://doi.org/10.1002/ajmg.1622
https://doi.org/10.1002/ajmg.1622
Publikováno v:
American journal of medical genetics. 114(1)
Imbalances in glutamatergic function have been implicated in the pathogenesis of neuropsychiatric disorders. Consequently, glutamate receptors genes are promising candidates in search of susceptibility genes for these disorders. In the present study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::162e509e252a860fd743e741106fecab
https://pubmed.ncbi.nlm.nih.gov/11840499
https://pubmed.ncbi.nlm.nih.gov/11840499
Publikováno v:
American journal of medical genetics. 114(1)
In the present study, we sought to identify genetic variation in the metabotropic glutamate receptor 3 (GRM3) gene, which has been mapped to chromosome 7q21.1-q21.2 [Scherer et al., 1996] and might contribute to genetic predisposition to schizophreni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3822ebc3fb90a5a171081a478d7deb9
https://pubmed.ncbi.nlm.nih.gov/11840505
https://pubmed.ncbi.nlm.nih.gov/11840505